RADX Radiopharm Theranostics Limited

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

RADX — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
14
List Date
2024-11-27
CIK
0001949257
Homepage
https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. It develops and commercializes radiopharmaceutical platforms for therapeutic and diagnostic applications in precision oncology. The Company develops targeted and scientifically validated radiopharmaceutical technologies in pre-clinical and clinical stages. It has one reportable segment, being the research, development, and commercialization of health technologies. The Company operates in Aus…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan--0.00%-2.13%-1.06%
Feb--12.87%-3.11%4.88%
Mar---12.55%-13.13%-12.84%
Apr---16.45%-1.16%-8.80%
May--16.25%3.85%10.05%
Jun---10.23%-10.47%-10.35%
Jul--9.63%-25.88%-8.12%
Aug--2.62%-26.69%-12.04%
Sep--2.22%-28.63%-13.21%
Oct---8.36%-27.03%-17.70%
Nov---6.56%-10.89%*-8.72%
Dec-74.59%12.02%---31.29%
Total-74.59%-5.07%-80.91%-53.52%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.99
SMA 50: $1.40
SMA 200: $3.56
Current: $0.89
EMA 12: $0.96
EMA 26: $1.10
MACD: -0.1445 | Signal: 0.0258
BEARISH
ADX (14): 27.45
TREND
+DI: 18.41
−DI: 24.91

Momentum Oscillators

RSI (14): 35.99
NEUTRAL
Stoch %K: 26.24
Stoch %D: 21.27
Williams %R: -78.62

Volume & Volatility

BB Upper: $1.17
BB Lower: $0.82
NEUTRAL
OBV: 34,757,281
Vol SMA 20: 60,087
Vol ROC: 4.60%
ATR: $0.16
True Range: $0.15
HV 20: 112.1%
HV 30: 102.9%
HV 60: 103.3%

Data Summary

Data Points: 477
Last Updated:
Date Range: 2024-12-05T00:00:00 – 2026-11-09T00:00:00
AI Analysis

LLM Stock Analysis Report: RADX

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers:

  • Positive news sentiment driven by clinical trial updates, business partnerships, and financial results
  • Technical signals support the bullish trend, with a strong MACD crossover and neutral RSI

Primary risks:

  • Regulatory changes or setbacks in clinical trials could negatively impact the stock
  • High beta (0.53) suggests the stock is more volatile than the market, increasing risk exposure

2-3 sentence investment thesis: RADX presents an attractive opportunity for investors seeking to capitalize on its promising pipeline of radiopharmaceuticals. The company's recent clinical updates and partnerships demonstrate a clear commitment to driving growth and improving patient outcomes. With a strong technical setup and positive news sentiment, RADX could be poised for further upside in the near-term.

Recent news sentiment impact: The recent news headlines are overwhelmingly positive, with all five articles highlighting business updates, clinical trial milestones, and financial results. This favorable sentiment has contributed to the stock's bullish momentum, suggesting that investors may be increasingly optimistic about RADX's growth potential.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bullish
  • Medium-term (1-3 months): Neutral
  • Long-term (3-12 months): Bullish

Support/Resistance Levels:

  • Upper band: $4.90
  • Middle band: $4.44
  • Lower band: $3.98

Momentum Signals:

  • RSI interpretation: Neutral (53.56)
  • MACD signal: Bullish crossover
  • Bollinger Bands position: Squeeze

Volume Analysis:

  • Volume SMA 20: 43903.60
  • On-Balance Volume (OBV): 37156018.35
  • Volume Rate of Change: -88.29%

News & Sentiment Analysis

Recent Headlines Summary:

  • Five articles highlight business updates, clinical trial milestones, and financial results
  • All articles have a positive sentiment

Sentiment Assessment: POSITIVE

Catalyst Identification:

  • Upcoming earnings report could provide further catalysts for the stock
  • Regulatory approvals or setbacks in clinical trials may impact the stock's performance

Market Narrative: The market narrative suggests that investors are increasingly optimistic about RADX's growth potential, driven by positive news sentiment and technical signals.

Risk & Volatility Assessment

Risk Interpretation: LOW RISK

Volatility Regime: CURRENT: Low volatility HISTORICAL: HV20 57.6%, HV30 51.3%, HV60 51.0%

Options Market Signals:

  • IV Premium vs HV30: N/A (positive = implied richer than realized)

Downside Protection: Support levels: $4.44, $3.98

Market Context & Positioning

Sector Performance: RADX is outperforming the broader market in the healthcare sector.

Institutional Activity: Volume patterns suggest institutional interest is moderate to high.

Correlation Analysis: R-squared interpretation suggests RADX moves relatively independently of the market.

Relative Valuation: Position within trading range: Bullish

Key Levels & Action Items

Critical Price Levels:

  • Support: $4.44, $3.98
  • Resistance: $4.90

Breakout/Breakdown Levels:

  • Breakout above upper band: $4.90
  • Breakdown below lower band: $3.98

Time-Sensitive Catalysts: Earnings report (TBD)

Risk Management: Stop-loss levels: $4.30, $3.80

Generated

RADX Options Activity & IV Rank

Loading options activity...
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 0.3519
Alpha: -82.46%
Correlation: 0.0282
R-Squared: 0.1%
Stock Volatility: 171.6%
Market Volatility: 13.7%

Analysis Details

Benchmark: SPY
Data Points: 249
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time

RADX Institutional Ownership (13F)

Filings for 2026-06-30 · 1 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

6 filers51,154,028 shares$1.18M value
# Filer Shares Value % of Total % of Float Period
1 Stonepine Capital Management, LLC 51,000,000 $670.50K 56.80% — 2026-06-30
2 HSBC Holdings plc Custodian 62,188 $253.73K 21.49% — 2026-06-30
3 Regal Partners Ltd 40,138 $168.18K 14.25% — 2026-06-30
4 PNC Financial Services Group, Inc. Custodian 50,000 $81.00K 6.86% — 2026-09-30
5 UBS Group AG Custodian 1,507 $6.31K 0.53% — 2026-06-30
6 RhumbLine Advisers 195 $817 0.07% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

RADX Insider Trading (Form 4)

Latest: 2026-10-27
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-27 Dimitris Voliotis Chief Medical Officer Grant (A) +30,887,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

RADX vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.21T 45.8 +45.5% +30.7% 27
JNJ Johnson & Johnson $664.9B 42.8 +7.8% +36.1% 54
ABBV ABBVIE INC. $514.9B 50.5 +10.7% +27.9% 30
MRK Merck & Co., Inc. $361.7B 153.4 +4.9% +39.7% 44
NVS Novartis AG $307.0B — — +18.2% 36
AZN AstraZeneca PLC $289.1B — — +106.8% 0
ABT Abbott Laboratories $190.4B 40.9 +10.0% −11.0% 20
NVO Novo-Nordisk A/S $177.7B — — −21.0% 15
RADX Radiopharm Theranostics Limited American $15M — — −82.8% —
Peer median $334.4B 45.8 +10.0% +29.3% 28

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.